Prasugrel with CAS 150322-43-3 is a platelet inhibitor for acute coronary syndromes planned for percutaneous coronary intervention.
Prasugrel (CAS 150322-43-3), Prasugrel is a prodrug and is rapidly metabolized to a pharmacologically active metabolite and inactive metabolites. The active metabolite has an elimination half-life of about 7 hr (range 2-15 hr). Healthy subjects, patients with stable atherosclerosis, and patients undergoing PCI show similar pharmacokinetics.
Viwit Pharmaceuticals Limited (Viwit), founded in 2006, is a fast-growing research-based pharmaceutical healthcare company dedicated to the development, manufacture and marketing of innovative products in the fields of Finished Dosage Formulations, Active Pharmaceutical Ingredients and Fine Chemicals. Viwit manufactures all the products based on company’s core technologies, and is dedicated to serve customers for their greater success and healthier living.
Viwit consists of six subsidiaries, in...
View more >>
Basic Information
Business Type: Manufacturer
Product/Service (We Buy): 101 - 500 People
Year Established: 2006
Number of Employees: 101 - 500 People
Trade & Market
Main Markets: North America,Mid East,Western Europe